$PBIO Pressure BioSciences to Expand on Upcoming Release of CBD Nanoemulsion Oral Spray at July 6th Emerging Growth Conference - Annual Revenue to PBI Expected to Exceed $1M
https://www.accesswire.com/707664/pressure-bi...-exceed-1m
Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive Update/Q&A Session
SOUTH EASTON, MA / ACCESSWIRE / July 6, 2022 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" and the "Company"
, a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company's participation in the July 6th Emerging Growth Investor Conference. This real-time, interactive conference will feature a number of exciting, rapidly-growing publicly traded companies, presenting for 30-45 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, will be speaking at 10:30 am ET. Mr. Schumacher will briefly expand on the Company's recent announcement of its contracted production launch of its first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use.
Last week, PBI announced the execution of an agreement with Safer Medical of Montana ("SMM" covering the production, distribution, commercial roll-out, and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM's roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under this agreement, PBI expects to realize more than $1M in revenue from SMM's $3M sales target. This is the first commercial product produced and marketed that uses the Company's patented Ultra Shear Technology™ (UST™) platform.
DATE: Wednesday, July 6, 2022 (10:30 am ET)
PRESENTATION: Video Webcast - Presentation plus Q&A
REGISTER: Click here to register for the conference
Highlights of PBI's Recent Press Release on the Contracted Production Launch of a UST-Processed, Nanoemulsified CBD Spray for Oral Use - with Estimated Annual Revenue to PBI Expected to Exceed $1,000,000:
PBI will release its first ever UST-processed product to the U.S. market over the next few months
This unique product is a long-term stable, highly water-soluble CBD aerosol spray for oral use
Formulation of the product has been completed: only plant-based reagents are used in the product
Safer Medical of Montana (SMM) will partner with PBI on production, distribution, commercial roll-out, and financial returns - terms of this partnership are in an agreement that was recently executed by the companies
SMM has existing distribution channels and infrastructure for its current health and wellness products
SMM estimates that first-year sales will meet or exceed $3M with revenue of over $1M belonging to PBI
SMM believes no other CBD oral spray available today can compete with the quality and water absorbability of the PBI UST-processed nanoemulsified product
https://www.accesswire.com/707664/pressure-bi...-exceed-1m
Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive Update/Q&A Session
SOUTH EASTON, MA / ACCESSWIRE / July 6, 2022 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" and the "Company" , a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company's participation in the July 6th Emerging Growth Investor Conference. This real-time, interactive conference will feature a number of exciting, rapidly-growing publicly traded companies, presenting for 30-45 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, will be speaking at 10:30 am ET. Mr. Schumacher will briefly expand on the Company's recent announcement of its contracted production launch of its first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use. Last week, PBI announced the execution of an agreement with Safer Medical of Montana ("SMM"
covering the production, distribution, commercial roll-out, and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM's roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under this agreement, PBI expects to realize more than $1M in revenue from SMM's $3M sales target. This is the first commercial product produced and marketed that uses the Company's patented Ultra Shear Technology™ (UST™) platform. DATE: Wednesday, July 6, 2022 (10:30 am ET)
PRESENTATION: Video Webcast - Presentation plus Q&A
REGISTER: Click here to register for the conference
Highlights of PBI's Recent Press Release on the Contracted Production Launch of a UST-Processed, Nanoemulsified CBD Spray for Oral Use - with Estimated Annual Revenue to PBI Expected to Exceed $1,000,000:
PBI will release its first ever UST-processed product to the U.S. market over the next few months
This unique product is a long-term stable, highly water-soluble CBD aerosol spray for oral use
Formulation of the product has been completed: only plant-based reagents are used in the product
Safer Medical of Montana (SMM) will partner with PBI on production, distribution, commercial roll-out, and financial returns - terms of this partnership are in an agreement that was recently executed by the companies
SMM has existing distribution channels and infrastructure for its current health and wellness products
SMM estimates that first-year sales will meet or exceed $3M with revenue of over $1M belonging to PBI
SMM believes no other CBD oral spray available today can compete with the quality and water absorbability of the PBI UST-processed nanoemulsified product
